Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is ...
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...
The Streetjournal Magazine is an online investigating media house that specializes on systematic, serious crimes, political ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback